Saturday 02 Aug, 2025 12:33 PM
Site map | Locate Us | Login
   G R Infra Q1 PAT surges 57% YoY to Rs 244 cr    ITC Q1 PAT rises 3% YoY to Rs 5,244 cr    Delhivery Q1 PAT climbs 68% YoY to Rs 91 cr    Oriental Rail Infra secures Rs 8.24-cr orders from Indian Railways    Honeywell Automation Q1 PAT slides 8% YoY to Rs 125 cr    NMDC iron ore production jumps 42% YoY in July 2025    RailTel Corp bags Rs 166-cr service order from BSNL    Maruti Suzuki reports 3% YoY sales growth in July 2025    Tata Motors slips as total sales slide 4% YoY in July 2025    Swiggy slides after Q1 net loss widens to Rs 1,197 cr    P&G Health spurts after PAT climbs over threefold to Rs 66 cr in Q1 FY26    SML Isuzu hits the roof after July sales climbs 19% YoY    PNB Housing Finance Ltd leads losers in 'A' group    Credo Brands Marketing Ltd leads losers in 'B' group    Volumes spurt at Chalet Hotels Ltd counter 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Alkem labs launches Ibuprofen, Famotidine tablets in US
04-Aug-21   09:14 Hrs IST

Ibuprofen and Famotidine tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis tablets, 800 mg/26.6 mg.

This combination medication is used to relieve pain from rheumatoid arthritis and osteoarthritis while decreasing the risk of developing an ulcer from Ibuprofen use.

This is the first generic approval of Duexis tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation,” the company said in a statement.

The announcement was made before market hours today, 4 August 2021.

Alkem Laboratories is a pharmaceutical company with global operations. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

The company's board will meet on 6 August 2021 to consider and approve financial results for the quarter ended on 30 June 2021.

The scrip is currently up 0.30% at Rs 3,520.15 on the BSE. In the past three months, the stock has gained 26.10% while the benchmark Sensex has added 12.28% during the same period.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 43136107
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited